Mark Cuban Cost Plus Drug Company Expands Access with Addition of Starjemza® (ustekinumab-hmny) to Give Patients More Power Over Prescription Costs

New biosimilar added to portfolio reinforces the company's commitment to transparency and access DALLAS, Nov. 6, 2025 /PRNewswire/ -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) today announced the addition of Starjemza®, a new biosimilar medication, to its growing portfolio of...